凝血酶市場規模、佔有率、成長分析（按產品、劑型、最終用戶和地區）－2025 年至 2032 年產業預測

預計 2023 年全球凝血酶市場規模將達到 6.284 億美元，到 2032 年將達到 10.1744 億美元，預測期內（2025-2032 年）的複合年成長率為 5.5%。

凝血酶市場因其在止血和血液凝固中的重要作用，特別是在外科和創傷環境中，正在經歷顯著成長。心血管和整形外科手術等外科手術的增加，以及老齡化人口對改善醫療保健的需求，是成長要素。重組凝血酶等技術創新提高了安全性和有效性，解決了人們對動物性產品的擔憂。此外，凝血酶在生物技術和製藥應用（如再生醫學和創傷治療）的應用不斷擴大，也促進了市場擴張。目前，北美憑藉其先進的醫療保健系統和優惠的報銷政策佔據該市場的主導地位，其次是歐洲。然而，新興的亞洲市場，特別是中國和印度，提供了巨大的成長潛力。然而，高製造成本、嚴格的法規以及其他止血劑的競爭等挑戰對市場擴張構成了風險。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 顧客購買行為分析

凝血酶市場規模（按產品和複合年成長率） (2025-2032)

• 市場概覽
• 牛凝血酶
• 人類凝血酶
• 重組凝血酶

凝血酶市場規模（依劑型分類）及複合年成長率（2025-2032）

• 市場概覽
• 粉末狀
• 解決方案

凝血酶市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 診斷中心
• 研究所

凝血酶市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 按部門分類的公司佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Baxter International Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• GE Healthcare
• Bayer AG
• CSL Behring
• Grifols
• Hualan Biological Engineering
• Haematologic Technologies Inc.
• Octapharma AG
• Omrix Biopharmaceuticals Ltd.
• Japan Blood Products Organization
• Mallinckrodt Pharmaceuticals
• Mochida Pharmaceutical Co. Ltd.

結論和建議

Global Thrombin Market size was valued at USD 628.4 million in 2023 and is poised to grow from USD 662.96 million in 2024 to USD 1017.44 million by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The thrombin market is experiencing notable growth, driven by its critical role in hemostasis and blood coagulation, particularly in surgical and trauma settings. Increasing surgical procedures, including cardiovascular and orthopedic surgeries, alongside a growing aging population demanding enhanced medical care, are key growth factors. Innovations like recombinant thrombin have improved safety and efficacy, addressing concerns related to animal-derived products. Additionally, thrombin's expanding applications in biotechnology and pharmaceuticals, such as regenerative medicine and wound healing, contribute to market expansion. North America currently dominates this market due to its advanced healthcare system and favorable reimbursement policies, followed by Europe, while emerging markets in Asia, notably China and India, present significant growth potential. However, challenges such as high manufacturing costs, strict regulations, and competition from other hemostatic agents pose risks to market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Thrombin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Thrombin Market Segments Analysis

Global Thrombin Market is segmented by Product, Dosage Form, End-User and region. Based on Product, the market is segmented into Bovine Thrombin, Human Thrombin and Recombinant Thrombin. Based on Dosage Form, the market is segmented into Powder Form and Solution Form. Based on End-User, the market is segmented into Hospitals, Diagnostic Centers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Thrombin Market

The global thrombin market is driven by the rising number of surgical procedures, influenced by an aging population and the growing prevalence of non-communicable diseases such as cardiovascular conditions and cancer. With over 310 million surgeries conducted annually worldwide, the demand for thrombin-based products continues to soar, as thrombin is utilized in around 65% of cardiovascular surgeries and 55% of orthopedic procedures for local hemostasis. Additionally, the shift towards more minimally invasive surgical techniques necessitates effective hemostatic solutions like thrombin, which play a critical role in ensuring successful patient outcomes and enhancing overall surgical efficiency.

Restraints in the Global Thrombin Market

The global thrombin market faces significant constraints due to the high costs associated with thrombin production, particularly in the case of recombinant thrombin, which is a sophisticated biotechnological product. These elevated prices restrict its accessibility and application, particularly in healthcare facilities in developing regions where financial resources are limited. Consequently, many of these institutions may opt for more economical hemostatic alternatives, limiting the expansion and utilization of thrombin products in these markets. The high production costs thus pose a barrier to broader market penetration, hindering the integration of advanced hemostatic solutions in economically challenged healthcare settings.

Market Trends of the Global Thrombin Market

The Global Thrombin market is witnessing a notable shift towards the adoption of recombinant thrombin products, driven by their superior safety, purity, and consistency compared to traditional bovine-derived alternatives. This trend is fueled by the increasing emphasis on patient safety and the demand for effective hemostatic agents in surgical procedures. Additionally, the rise of minimally invasive surgical techniques necessitates reliable hemostasis, further propelling the utilization of advanced thrombin solutions. As healthcare providers seek to enhance procedural outcomes while minimizing complications, the preference for recombinant thrombin products is set to gain momentum, shaping the future landscape of the thrombin market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Thrombin Market Size by Product & CAGR (2025-2032)

• Market Overview
• Bovine Thrombin
• Human Thrombin
• Recombinant Thrombin

Global Thrombin Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Powder Form
• Solution Form

Global Thrombin Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutions

Global Thrombin Market Size & CAGR (2025-2032)

• North America (Product, Dosage Form, End-User)
  • US
  • Canada
• Europe (Product, Dosage Form, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Dosage Form, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Dosage Form, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Dosage Form, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haematologic Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omrix Biopharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Blood Products Organization
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mochida Pharmaceutical Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations